{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T06:52:05Z","timestamp":1793602325800,"version":"4.5.0"},"reference-count":113,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2024,7,2]]},"DOI":"10.1080\/13543776.2024.2314296","type":"journal-article","created":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T15:29:42Z","timestamp":1706974182000},"page":"547-564","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Patented Farnesoid X receptor modulators: a review (2019 \u2013 present)"],"prefix":"10.1080","volume":"34","author":[{"given":"Antimo","family":"Gioiello","sequence":"first","affiliation":[{"name":"Laboratory of Medicinal and Advanced Synthetic Chemistry (Lab MASC), Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Rosatelli","sequence":"additional","affiliation":[{"name":"Tes Pharma, Taverne di Corciano, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Cerra","sequence":"additional","affiliation":[{"name":"Laboratory of Medicinal and Advanced Synthetic Chemistry (Lab MASC), Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00404-2"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2017.10.003"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.06.009"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1119(02)00557-7"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M209505200"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5418.1362"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2014.08.005"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2005.09.001"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M700330-JLR200"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.cellbio.16.1.459"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35496-z"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.4161\/gmic.25723"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.212159"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2009.102"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0222-4"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/mSystems.00070-16"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI76738"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10166"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.201900608"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2018.03.016"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030443"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803978"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.12.005"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29569"},{"key":"e_1_3_4_27_1","unstructured":"Clinical trial: safety tolerability pharmacokinetics and efficacy of LMB763 in patients with NASH (NCT02913105). [cited 2023 Oct 27]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/results\/NCT02913105."},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61933-4"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.05.042"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2022.111678"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-023-01035-1"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/9783527808694.ch8"},{"key":"e_1_3_4_33_1","unstructured":"Clinical trial: study of INT-747 as monotherapy in participants with primary biliary cirrhosis (PBC) (NCT00570765). [cited 2023 Oct 27]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00570765."},{"key":"e_1_3_4_34_1","unstructured":"Clinical trial: study of INT 747 in combination with urso in patients with primary biliary cirrhosis (PBC) (NCT00550862). [cited 2023 Oct 27]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00550862."},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm025529g"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.11648\/j.ijg.20190301.12"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.07.034"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00907"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30509"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01161"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01621"},{"key":"e_1_3_4_42_1","first-page":"1049A","article-title":"MET409, a potent, novel, non-bile acid FXR agonist, in rodents and cynomolgus monkeys","volume":"68","author":"Wagner B","year":"2017","unstructured":"Wagner B, Govek S, Nagasawa J, et al. MET409, a potent, novel, non-bile acid FXR agonist, in rodents and cynomolgus monkeys. Hepatol. 2017;68:1049A.","journal-title":"Hepatol"},{"key":"e_1_3_4_43_1","article-title":"In vitro characterization of Eyp001 a novel, potent and selective FXR agonist entering phase 2 clinical trials in chronic hepatitis B","volume":"70","author":"Darteil R","year":"2019","unstructured":"Darteil R, Joly S, Radreau P, et al. In vitro characterization of Eyp001 a novel, potent and selective FXR agonist entering phase 2 clinical trials in chronic hepatitis B. Hepatol. 2019;70. Abstract 87.","journal-title":"Hepatol"},{"key":"e_1_3_4_44_1","unstructured":"[cited 2023 Oct 27]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/166997176"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.07.022"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.112"},{"key":"e_1_3_4_47_1","volume-title":"Late breaking abstract at: the Liver Meeting 2023","author":"Levy C","year":"2023","unstructured":"Levy C, Hejda V, Louvet A, et al. Combined effect of obeticholic acid and bezafibrate in patients with primary biliary cholangitis and inadequate response to or intolerance of ursodeoxycholic acid: results from two clinical trials. Late breaking abstract at: the Liver Meeting 2023; Nov 13, 2023; Boston, MA. Abstract 5019."},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2021.04.029"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2018.1459569"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568026614666141112100208"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568026614666141112094058"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01017"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.114.214650"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml200256d"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M300215-JLR200"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b01126"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15767"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113380"},{"key":"e_1_3_4_59_1","unstructured":"Intercept Pharmaceuticals Inc. Farnesoid x receptor modulators. US11034717 (granted patent). 2021."},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.7b00318"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm049904b"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.110.064501"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm501273r"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm060294k"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115851"},{"key":"e_1_3_4_66_1","volume-title":"American Diabetes Association (ADA) 73rd Scientific Sessions","author":"Wang X","unstructured":"Wang X, Qiu L, Hazra S, et al. Dual activation of FXR and TGR5 protects from diabetic nephropathy and retinopathy in mouse model of type 1 diabetes. American Diabetes Association (ADA) 73rd Scientific Sessions, Jun 21-25, 2013; Chicago, Illinois."},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24537"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-17-0557"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S170518"},{"key":"e_1_3_4_70_1","unstructured":"Clinical trial: safety tolerability pharmacokinetics and pharmacodynamics of BAR 502 in healthy subjects (NCT 05203367). [cited 2023 Oct 27]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05203367."},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep42801"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2011.03.004"},{"key":"e_1_3_4_73_1","unstructured":"Wen\u2019anluo Institute Shanghai Institute of Materia Medica of CAS. Cholic acid derivatives and its preparation method and application. CN110343140 (application). 2019."},{"key":"e_1_3_4_74_1","unstructured":"The regents of the University of California. Bile acids and use in disease treatment. WO2020154397 (application). 2020."},{"key":"e_1_3_4_75_1","unstructured":"Enanta Pharmaceuticals Inc. Bile acid derivatives as FXR\/TGR5 agonists and methods of use thereof. US11040998 (granted patent). 2021."},{"key":"e_1_3_4_76_1","unstructured":"Zhenjiang Shengan Pharmaceutical Co ltd and Jiangsu Jibeier Pharmaceutical Co ltd. Tauroursodeoxycholic acid derivative and pharmaceutical composition and preparation comprising same. CN112142814 (granted patent). 2021."},{"key":"e_1_3_4_77_1","unstructured":"Intercept Pharmaceuticals Inc. 3-desoxy derivative and pharmaceutical compositions thereof. US11319337B2 (granted patent 2022)."},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1097-2765(03)00112-6"},{"key":"e_1_3_4_79_1","unstructured":"Nzp Uk Ltd University of Southampton. Fluorinated bile acid derivatives. US11517577 (granted patent). 2022."},{"key":"e_1_3_4_80_1","unstructured":"Hepaitech (Beijing) Biopharma Technology. Polycyclic compounds and methods thereof. WO2023083343A1 (application). 2023."},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1903316116"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.19852\/j.cnki.jtcm.20230404.002"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.772435"},{"key":"e_1_3_4_84_1","unstructured":"Shanghai Institute of Materia Medica of CAS. Pentacyclic triterpenoid and preparation method pharmaceutical composition and application thereof. CN109517022 (granted patent 2022)."},{"key":"e_1_3_4_85_1","unstructured":"Yale University. Methods of inducing or enhancing farnesoid x receptor (fxr)-mediated transcriptional response. WO2021102124 (application 2020)."},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.19540\/j.cnki.cjcmm.20200902.601"},{"key":"e_1_3_4_87_1","unstructured":"Jiangxi University of Traditional Chinese Medicine. Oleanane-type triterpenic acid and composition thereof and preparation method and application thereof. CN114057825 (application 2021)."},{"key":"e_1_3_4_88_1","unstructured":"Shanghai Institute of Materia Medica of CAS. Tricyclic FXR receptor antagonist and preparation method thereof. CN115504880 (application 2021)."},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0002127"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.05.070"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(03)00104-7"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1039\/b300525a"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3760"},{"key":"e_1_3_4_94_1","unstructured":"Metacrine Inc. Farnesoid x receptor agonists and uses thereof. WO2020061113 (application 2020)."},{"key":"e_1_3_4_95_1","unstructured":"Metacrine Inc. Farnesoid x receptor agonists for the treatment of disease. WO2021188688 (application 2021)."},{"key":"e_1_3_4_96_1","unstructured":"Bristol Myers Squibb Co. Substituted amide compounds useful as farnesoid x receptor modulators. US20220213026 (application 2020)."},{"key":"e_1_3_4_97_1","unstructured":"Bristol Myers Squibb Co. Substituted bicyclic compounds as farnesoid X receptor modulators. US11254663 (granted patent 2022)."},{"key":"e_1_3_4_98_1","unstructured":"Bar Pharmaceuticals S.r.l. Oxadiazoles as fxr receptor antagonists. WO2019224743 (application 2019)."},{"key":"e_1_3_4_99_1","unstructured":"Henan University. Application of benzbromarone as FXR agonist. CN111265511 (application 2020)."},{"key":"e_1_3_4_100_1","unstructured":"Poxel. Pharmaceutical combination of a specific thienopyridone derivative with an fxr agonist for the treatment of liver diseases. WO2021037702 (application 2021)."},{"key":"e_1_3_4_101_1","unstructured":"Clinical trial: study to assess the safety tolerability and pharmacokinetics of PXL770 in healthy subjects (NCT05441904). [cited 2023 Oct 27]. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05441904."},{"key":"e_1_3_4_102_1","unstructured":"Enanta Pharmaceuticals Inc. Bile acid derivatives as FXR\/TGR5 agonists and methods of use thereof. US10208081 (granted patent 2019)."},{"key":"e_1_3_4_103_1","unstructured":"Enanta Pharmaceuticals Inc. Process for preparation of sulfonylurea bile acid derivatives. US10584145 (granted patent 2020)."},{"key":"e_1_3_4_104_1","unstructured":"Phenex Pharmaceuticals Ag. Novel fxr (nr1h4) binding and activity modulating compounds. WO2013007387 (application 2013)."},{"key":"e_1_3_4_105_1","unstructured":"Gilead Sciences Inc. FXR (NR1H4) binding and activity modulating compounds. US9139539 (granted patent 2015)."},{"key":"e_1_3_4_106_1","unstructured":"Sichuan Kelun Biotech Biopharmaceutical Co Ltd. Preparation method of compound serving as farnesoid X receptor agonist. CN 115215853 (application 2022)."},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1039\/C9MD00264B"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep14086"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10853-2"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00831"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202100118"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2011.06.012"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113577"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01918"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26187"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2024.2314296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T22:45:25Z","timestamp":1727217925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2024.2314296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":113,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,2]]}},"alternative-id":["10.1080\/13543776.2024.2314296"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2024.2314296","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}